Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC
Heymach J, Hanrahan E, Mann H, Langmuir P, Natale R, Johnson B, Herbst R, Ryan A. Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC. Journal Of Clinical Oncology 2008, 26: 8009-8009. DOI: 10.1200/jco.2008.26.15_suppl.8009.Peer-Reviewed Original Research